Thorax:慢性阻塞性肺病患者健康状况变化和随访结果

2015-06-02 徐媛媛译 MedSci原创

在COPD患者中,不良的健康状况与发病率和死亡率具有相关性。到目前为止,健康状况的改变对COPD患者的影响还不是很明确。本研究旨在探讨健康状况的相关临床变化与COPD患者病情加重、住院或死亡之间的联系。 本研究共纳入2138名COPD患者,通过健康状况(圣乔治呼吸问卷,SGRQ)评分来评估COPD患者在超过3年时间里慢性阻塞性肺病在ECLIPSE研究中的纵向识别替代终点。使用KM曲线和log-r

在COPD患者中,不良的健康状况与发病率和死亡率具有相关性。到目前为止,健康状况的改变对COPD患者的影响还不是很明确。本研究旨在探讨健康状况的相关临床变化与COPD患者病情加重、住院或死亡之间的联系。

本研究共纳入2138名COPD患者,通过健康状况(圣乔治呼吸问卷,SGRQ)评分来评估COPD患者在超过3年时间里慢性阻塞性肺病在ECLIPSE研究中的纵向识别替代终点。使用KM曲线和log-rank检测评估第一年健康状况(=SGRQ分数4个单位的改变)与在接下来2年随访中加重时间、住院、死亡之间的关系。

研究人员对1832(85.7%) 名患者(年龄63.4±7.0岁,65.4%为男性,FEV1 48.7±15.6%预测值)在基线期和第1年间进行了评估。与第一年健康状况恶化的患者相比,健康状况改善或稳定的患者在第2年的随访中,COPD恶化的可能性较低(HR 0.78(95%CI,0.67-0.89)p<0.001和HR 0.84(95%CI,0.73-0.97)p<0.016)、住院(0.72 (0.58 to 0.90), p=0.004 和0.77 (0.62 to 0.96), p=0.023)和死亡(0.61 (0.39 to 0.95), p=0.027和0.58 (0.37 to 0.92), p=0.019)。在对年龄、第一年加重和住院次数进行分层后,以上研究结果依然存在。

基于以上结果,改善健康状况的干预措施会改善COPD患者的不良结果。

原始出处

Wilke S1, Jones PW2, Müllerova H3, Vestbo J4, Tal-Singer R5, Franssen FM1, Agusti A6, Bakke P7, Calverley PM8, Coxson HO9, Crim C10, Edwards LD10, Lomas DA11, MacNee W12, Rennard SI13, Yates JC10, Wouters EF14, Spruit MA15.One-year change in health status and subsequent outcomes in COPD.Thorax. 2015 May;

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1696650, encodeId=08321696650a7, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jul 30 18:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671839, encodeId=0ce516e18394b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Mar 20 18:36:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818765, encodeId=86321818e65de, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jul 30 16:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510977, encodeId=050c15109e744, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Jun 04 01:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25758, encodeId=6b8325e5823, content=有意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouanxiu, createdTime=Tue Jun 02 12:52:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25754, encodeId=0d3925e54e7, content=大家须努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jxsrdw, createdTime=Tue Jun 02 11:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-07-30 tomyang96
  2. [GetPortalCommentsPageByObjectIdResponse(id=1696650, encodeId=08321696650a7, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jul 30 18:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671839, encodeId=0ce516e18394b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Mar 20 18:36:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818765, encodeId=86321818e65de, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jul 30 16:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510977, encodeId=050c15109e744, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Jun 04 01:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25758, encodeId=6b8325e5823, content=有意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouanxiu, createdTime=Tue Jun 02 12:52:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25754, encodeId=0d3925e54e7, content=大家须努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jxsrdw, createdTime=Tue Jun 02 11:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2016-03-20 amy0559
  3. [GetPortalCommentsPageByObjectIdResponse(id=1696650, encodeId=08321696650a7, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jul 30 18:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671839, encodeId=0ce516e18394b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Mar 20 18:36:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818765, encodeId=86321818e65de, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jul 30 16:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510977, encodeId=050c15109e744, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Jun 04 01:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25758, encodeId=6b8325e5823, content=有意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouanxiu, createdTime=Tue Jun 02 12:52:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25754, encodeId=0d3925e54e7, content=大家须努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jxsrdw, createdTime=Tue Jun 02 11:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1696650, encodeId=08321696650a7, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jul 30 18:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671839, encodeId=0ce516e18394b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Mar 20 18:36:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818765, encodeId=86321818e65de, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jul 30 16:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510977, encodeId=050c15109e744, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Jun 04 01:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25758, encodeId=6b8325e5823, content=有意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouanxiu, createdTime=Tue Jun 02 12:52:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25754, encodeId=0d3925e54e7, content=大家须努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jxsrdw, createdTime=Tue Jun 02 11:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1696650, encodeId=08321696650a7, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jul 30 18:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671839, encodeId=0ce516e18394b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Mar 20 18:36:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818765, encodeId=86321818e65de, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jul 30 16:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510977, encodeId=050c15109e744, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Jun 04 01:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25758, encodeId=6b8325e5823, content=有意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouanxiu, createdTime=Tue Jun 02 12:52:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25754, encodeId=0d3925e54e7, content=大家须努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jxsrdw, createdTime=Tue Jun 02 11:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-02 zhouanxiu

    有意

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1696650, encodeId=08321696650a7, content=<a href='/topic/show?id=d2e99e651e4' target=_blank style='color:#2F92EE;'>#阻塞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=97651, encryptionId=d2e99e651e4, topicName=阻塞)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a23129903429, createdName=tomyang96, createdTime=Thu Jul 30 18:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1671839, encodeId=0ce516e18394b, content=<a href='/topic/show?id=58378220131' target=_blank style='color:#2F92EE;'>#肺病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82201, encryptionId=58378220131, topicName=肺病)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2f0826868454, createdName=amy0559, createdTime=Sun Mar 20 18:36:00 CST 2016, time=2016-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1818765, encodeId=86321818e65de, content=<a href='/topic/show?id=9687984e5e3' target=_blank style='color:#2F92EE;'>#随访结果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98475, encryptionId=9687984e5e3, topicName=随访结果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=778d36, createdName=柳叶一刀, createdTime=Thu Jul 30 16:36:00 CST 2015, time=2015-07-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1510977, encodeId=050c15109e744, content=<a href='/topic/show?id=5a822e867b5' target=_blank style='color:#2F92EE;'>#健康状况#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=27867, encryptionId=5a822e867b5, topicName=健康状况)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e3710287449, createdName=kkunny, createdTime=Thu Jun 04 01:36:00 CST 2015, time=2015-06-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25758, encodeId=6b8325e5823, content=有意, beContent=null, objectType=article, channel=null, level=null, likeNumber=104, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=zhouanxiu, createdTime=Tue Jun 02 12:52:00 CST 2015, time=2015-06-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=25754, encodeId=0d3925e54e7, content=大家须努力, beContent=null, objectType=article, channel=null, level=null, likeNumber=169, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=jxsrdw, createdTime=Tue Jun 02 11:22:00 CST 2015, time=2015-06-02, status=1, ipAttribution=)]
    2015-06-02 jxsrdw

    大家须努力

    0

相关资讯

β受体阻断剂在COPD的治疗或使用不足

    β受体阻断剂在慢性阻塞性肺病(COPD)的治疗中可能使用不足,而在急性心肌梗死的早期治疗中则存在使用过度的情况。     心血管疾病与COPD经由吸烟而形成了错综复杂的关系,然而对COPD患者使用β受体阻断剂却与传统观念相悖。多数医生都会避免这样做,哪怕患者合并心血管疾病,原因是担心β受体阻断剂诱发支气管痉挛和抵消β受体激动剂吸

COPD三联疗法(FF/UMEC/VI)III期临床研究启动(IMPACT试验)

葛兰素史克(GSK)和Theravance公司近日联合宣布,启动慢性阻塞性肺病(COPD)三联疗法(FF/UMEC/VI)III期临床项目首个全球、关键III期IMPACT研究。该三联疗法(FF/UMEC/VI)是一种ICS/LAMA/LABA组合疗法,IMPACT研究将评估该三联疗法(FF/UMEC/VI)用于COPD治疗的疗效和安全性。IMPACT是一项双盲、3个治疗组、平行组研究,将招募

APJCN:用机械通气的慢性阻塞性肺病患者测定的与预测的静息能量消耗之比较及临床应用分析

为了研究机械通气的慢性阻塞性肺病(COPD)患者的能量代谢特点,比较间接测热法测定与Harris-Benedict公式预测的静息能量消耗(REE)的差异。并以此为依据,分析低能量的营养支持是否能改善患者蛋白质营养状况。【原文下载】 纳入了33例(男20例,女13例)COPD患者,并测定其REE。比较测定的REE(REEm)和HB公式计算的REE(REEH-B)及其校正值之间的差异,同时还分析了R

PLoS One:Tiotropium治疗慢性阻塞性肺病效果略优于Indacaterol

每日两次吸入支气管扩张剂indacaterol和tiotropium被广泛应用于慢性阻塞性肺病的一线临床治疗。 本研究旨在比较indacaterol和tiotropium在治疗中度到重度慢性阻塞性肺病患者中的临床疗效和安全性。 我们检索了MEDLINE, EMBASE和Cochrane Central Register of Controlled Trials数据库并收集整理了所有发表的相